IL157874A0 - The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene - Google Patents

The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene

Info

Publication number
IL157874A0
IL157874A0 IL15787402A IL15787402A IL157874A0 IL 157874 A0 IL157874 A0 IL 157874A0 IL 15787402 A IL15787402 A IL 15787402A IL 15787402 A IL15787402 A IL 15787402A IL 157874 A0 IL157874 A0 IL 157874A0
Authority
IL
Israel
Prior art keywords
triazatetracyclo
pentaene
hexadeca
citrate salt
citrate
Prior art date
Application number
IL15787402A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157874(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL157874A0 publication Critical patent/IL157874A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
IL15787402A 2001-05-14 2002-04-26 The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene IL157874A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14
PCT/IB2002/001450 WO2002092597A1 (en) 2001-05-14 2002-04-26 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
IL157874A0 true IL157874A0 (en) 2004-03-28

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15787402A IL157874A0 (en) 2001-05-14 2002-04-26 The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene

Country Status (37)

Country Link
US (1) US6787549B2 (https=)
EP (1) EP1390366B1 (https=)
JP (1) JP4137645B2 (https=)
KR (1) KR20040008175A (https=)
CN (1) CN1509288A (https=)
AP (1) AP1429A (https=)
AR (1) AR035889A1 (https=)
AT (1) ATE303386T1 (https=)
BG (1) BG108344A (https=)
CA (1) CA2446988A1 (https=)
CZ (1) CZ20032917A3 (https=)
DE (1) DE60205888T2 (https=)
DO (1) DOP2002000390A (https=)
DZ (1) DZ3503A1 (https=)
EA (1) EA005529B1 (https=)
EE (1) EE200300557A (https=)
ES (1) ES2245731T3 (https=)
GT (1) GT200200081A (https=)
HR (1) HRP20030911A2 (https=)
HU (1) HUP0304085A3 (https=)
IL (1) IL157874A0 (https=)
IS (1) IS6956A (https=)
MA (1) MA27021A1 (https=)
MX (1) MXPA03010365A (https=)
MY (1) MY134123A (https=)
NO (1) NO20035035D0 (https=)
NZ (1) NZ528209A (https=)
OA (1) OA12600A (https=)
PA (1) PA8545001A1 (https=)
PE (1) PE20021095A1 (https=)
PL (1) PL366774A1 (https=)
SK (1) SK13372003A3 (https=)
TN (1) TNSN03112A1 (https=)
UA (1) UA73421C2 (https=)
UY (1) UY27287A1 (https=)
WO (1) WO2002092597A1 (https=)
ZA (1) ZA200307234B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50069B (sr) * 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
WO2003045437A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP2086977A2 (en) * 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphs of nicotinic intermediates
WO2009109651A1 (en) * 2008-03-06 2009-09-11 Medichem, S.A. SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
PL2376499T3 (pl) * 2008-12-11 2015-07-31 Cti Biopharma Corp Sól cytrynianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26-triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
WO2013163917A1 (zh) 2012-04-13 2013-11-07 连云港金康和信药业有限公司 化合物jk12a及其制备
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
CN115968283B (zh) * 2020-03-16 2024-11-22 成都科岭源医药技术有限公司 5-ht3受体调节剂、晶型、制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50069B (sr) * 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
AP2002002522A0 (en) 2002-06-30
DOP2002000390A (es) 2003-03-15
AR035889A1 (es) 2004-07-21
US6787549B2 (en) 2004-09-07
UY27287A1 (es) 2003-02-28
HUP0304085A3 (en) 2005-09-28
EP1390366A1 (en) 2004-02-25
OA12600A (en) 2006-06-09
MA27021A1 (fr) 2004-12-20
EP1390366B1 (en) 2005-08-31
KR20040008175A (ko) 2004-01-28
BG108344A (bg) 2004-12-30
EE200300557A (et) 2004-04-15
WO2002092597A1 (en) 2002-11-21
GT200200081A (es) 2003-04-22
HUP0304085A2 (en) 2004-04-28
IS6956A (is) 2003-09-15
CN1509288A (zh) 2004-06-30
MXPA03010365A (es) 2004-03-16
HRP20030911A2 (en) 2004-02-29
JP2004529186A (ja) 2004-09-24
NO20035035L (no) 2003-11-13
SK13372003A3 (sk) 2004-08-03
ZA200307234B (en) 2004-09-16
NO20035035D0 (no) 2003-11-13
ES2245731T3 (es) 2006-01-16
US20030149091A1 (en) 2003-08-07
EA200301120A1 (ru) 2004-02-26
PL366774A1 (en) 2005-02-07
PA8545001A1 (es) 2003-09-05
PE20021095A1 (es) 2002-12-14
CA2446988A1 (en) 2002-11-21
DZ3503A1 (https=) 2002-11-21
JP4137645B2 (ja) 2008-08-20
TNSN03112A1 (fr) 2005-12-23
EA005529B1 (ru) 2005-04-28
MY134123A (en) 2007-11-30
DE60205888T2 (de) 2006-07-06
CZ20032917A3 (cs) 2004-07-14
ATE303386T1 (de) 2005-09-15
AP1429A (en) 2005-06-13
UA73421C2 (en) 2005-07-15
NZ528209A (en) 2004-09-24
DE60205888D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
DE60205742D1 (de) Tartrate des 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaens
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
IL160081A0 (en) Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
IL157874A0 (en) The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
ZA200410015B (en) Pharmaceutical salts.
MXPA03008590A (es) Derivados del factor vii de coagulacion.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
ZA200400926B (en) Diamine derivatives.
ZA200308717B (en) Herbicidal composition.
MXPA03008216A (es) Derivados de 3-fenilo.
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
MXPA03007539A (es) Composicion herbicida.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
MXPA03009002A (es) 5-halogeno-6-fenil-7-fluoroalquilamino-triazolopirimidinas.
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
GB0130553D0 (en) 1,4-Dihydro-1,4-diphenylpyridine derivitives
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
PL370715A1 (en) [1.2]-oxazin-3,5-diones
MXPA03008394A (es) Derivados de biuretano.
MXPA03009409A (es) Composicion herbicida.
EG23417A (en) Process for the preparation 7 a-methylsteroids.
EG23429A (en) Novel a-oxygenated or a-thiolated carboxylic acid phenethylamide derivatives.